Charles River (CRL) has recently announced two strategic collaborations across its contract development and manufacturing organization, aimed at advancing novel oncology research and development. These collaborations include forming an alliance with the Parker Institute for Cancer Immunotherapy and supporting a streamlined manufacturing process for Children’s Hospital Los Angeles’ Phase I Clinical Trials. Charles River has formed a strategic alliance with the Parker Institute for Cancer Immunotherapy. As part of the strategic alliance, PICI network members and their companies will have access to Charles River’s portfolio of preclinical drug discovery and development services, ranging from early discovery to manufacturing. Through a recent agreement, Charles River’s C> capabilities and dedicated CDMO Centers of Excellence will generate materials to support the advancement of a Phase I Clinical Trial at Children’s Hospital Los Angeles.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRL:
- Lululemon downgraded, Dick’s Sporting upgraded: Wall Street’s top analyst calls
- Charles River upgraded to Buy from Hold at Jefferies
- Charles River, Akadeum Life Sciences announce collaboration
- Charles River price target raised to $211 from $189 at Rothschild & Co Redburn
- Charles River Labs: Stability and Long-term Value Creation Potential Amidst Short-term Challenges